Aprea Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APRE research report →
Price Chart
About the company
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways.
- CEO
- Oren Gilad
- IPO
- 2019
- Employees
- 8
- HQ
- Boston, PA, US
Get TickerSpark's AI analysis on APRE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.92M
- P/E
- -0.50
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.89
- EV/EBITDA
- 2.71
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -46.72%
- ROIC
- -33.73%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-13,233,836
- Net Income
- $-12,599,569+2.8%
- EPS
- $-1.93+17.9%
- OCF Growth
- +4.9%
- FCF Growth
- +5.0%
- 52W High
- $1.70
- 52W Low
- $0.55
- 50D MA
- $0.70
- 200D MA
- $0.85
- Beta
- 1.59
- RSI (14)
- 43
- Avg Volume
- 83.01K
No earnings-call transcripts are available for APRE yet.
- Free Float
- 86.4%
- Shares Outstanding
- 12.38M
- Float Shares
- 10.70M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 58.09K | ▼ 100.15K |
Held by 4 ETFs
Biggest fund positions in APRE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Grissinger Michael | other | 12,555 |
| Jun 16, 26 | Grissinger Michael | other | 3,135 |
| Jun 16, 26 | Gruia Gabriela | other | 12,555 |
| Jun 16, 26 | Gruia Gabriela | other | 3,135 |
| Jun 16, 26 | Peters Richard | other | 12,555 |
| Jun 16, 26 | Peters Richard | other | 3,135 |
| Jun 16, 26 | HENNEMAN JOHN B III | other | 3,135 |
| Jun 16, 26 | HENNEMAN JOHN B III | other | 12,555 |
| Jun 16, 26 | BIZZARI JEAN-PIERRE | other | 12,555 |
| Jun 16, 26 | BIZZARI JEAN-PIERRE | other | 3,135 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APRE coverage
Recent articles, reports, and earnings notes.
No research on APRE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APRE report →Aprea Therapeutics Announces Second Quarter 2026 Financial Results
globenewswire.com · Aug 12
Lipocine Appoints Michael J. Grissinger to Board of Directors
prnewswire.com · Aug 3
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
globenewswire.com · Jul 30
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
globenewswire.com · Jun 1
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know
zacks.com · May 21
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
globenewswire.com · May 13
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More
247wallst.com · May 7
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
globenewswire.com · Apr 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.